NASDAQ: NVCN
TSX: NVC
VANCOUVER, Nov. 2, 2016 /CNW/ - Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX:
NVC) announced today its notable presentations at the annual
Transcatheter Cardiovascular Therapeutics (TCT) symposium, the
world's largest educational meeting specializing in interventional
cardiovascular medicine held in Washington, DC.
On October 31, Dr. Anson Cheung from St.
Paul's hospital, Vancouver,
Canada presented an update on the ongoing Tiara™ program. He
presented the clinical data to date, on the 19 patients treated
with the Tiara™ valve. The 30-day survival rate for these 19
patients is 84%. Overall, the data presented was very
encouraging, in this very sick cohort of patients treated with
Tiara.
Dr. Cheung elaborated that enrolment continues in the TIARA-I
Early Feasibility Trial and in other compassionate use programs.
The TIARA-I trial is assessing the safety and performance of the
Tiara™ mitral valve system and the implantation procedure in
high-risk patients suffering from severe mitral regurgitation.
Dr. Florian Deuschl from
Hamburg, Germany gave a
presentation entitled, Echocardiographic Guiding of a Novel Mitral
Valve Replacement, which reviewed his positive experience from the
Tiara implantation cases performed by the team in
Hamburg.
With respect to the Company's other cardiovascular device, the
Neovasc Reducer™, for the treatment of Refractory Angina, Dr.
Gregg Stone presented the Reducer as
the most effective treatment option for patients suffering from
refractory angina despite optimal medical therapy. He
reviewed the results of the COSIRA randomized study which was
published in the New England Journal of Medicine last year.
He also outlined the design of the COSIRA II, pivotal US trial,
which will include 380 patients and will be a multicenter
prospective, randomized, double-blind, sham-controlled trial.
In addition, during the conference there were two posters
presented from Italy, describing
the positive effect of the Neovasc Reducer™.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products in development
include the Tiara™, for the transcatheter treatment of mitral valve
disease and the Neovasc Reducer™ for the treatment of refractory
angina. The Company also sells a line of advanced biological tissue
products that are used as key components in third-party medical
products including transcatheter heart valves. For more
information, visit: www.neovasc.com.
This news release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and applicable Canadian securities laws, including statements
that the study found Reducer implantation to be the most effective
treatment option for patients suffering from refractory angina
despite optimal medical therapy and the proposed design of the
COSIRA II pivotal US trial. The words "most effective" and
"will" are intended to identify these forward-looking
statements. Forward-looking statements are based on estimates
and assumptions made by the Company in light of its experience and
its perception of historical trends, current conditions and
expected future developments, as well as other factors that the
Company believes are appropriate in the circumstances. Many
factors and assumptions could cause the Company's actual results,
performance or achievements to differ materially from those
expressed or implied by the forward-looking statements, including,
without limitation, potential changes in circumstances relating to
the Company's financing requirements, whether as a result of
unforeseen circumstances or otherwise; the conduct or possible
outcomes of any actual or threatened legal proceedings, including
any post-trial motions or appeals, which are inherently uncertain;
the potential benefits of the Neovasc Reducer™ and Tiara™ as
compared with other products; successful enrollment of patients in
studies and trials for the Neovasc Reducer™ and Tiara™; results of
the trials and studies for the Neovasc Reducer™ and Tiara™ that
meet the Company's expectations; the Company's receipt of any
required local and institutional regulatory approvals and the
timing and costs of obtaining such approvals; European enrollment
in our clinical trials, studies and compassionate use cases and the
success of applications in Europe; the Company's ability to
protect its intellectual property; the Company's ability to raise
additional funding; changes in business strategy or development
plans; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations and general
economic and business conditions, both nationally and in the
regions in which the Company operates. These risk factors and
others relating to the Company are discussed in greater detail in
the "Risk Factors" section of the Company's Annual Information
Form, which is included in its Annual Report on Form 40-F (copies
of which filings may be obtained
at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company's forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
SOURCE Neovasc Inc.